作者
Carlotta Buzzoni, Anssi Auvinen, Monique J Roobol, Sigrid Carlsson, Sue M Moss, Donella Puliti, Harry J De Koning, Chris H Bangma, Louis J Denis, Maciej Kwiatkowski, Marcos Lujan, Vera Nelen, Alvaro Paez, Marco Randazzo, Xavier Rebillard, Teuvo LJ Tammela, Arnauld Villers, Jonas Hugosson, Fritz H Schröder, Marco Zappa
发表日期
2015/11/1
期刊
European urology
卷号
68
期号
5
页码范围
885-890
出版商
Elsevier
简介
Background
The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer (PCa) mortality and a 1.6-fold increase in PCa incidence with prostate-specific antigen (PSA)-based screening (at 13 yr of follow-up). We evaluated PCa incidence by risk category at diagnosis across the study arms to assess the potential impact on PCa mortality.
Design, setting, and participants
Information on arm, centre, T and M stage, Gleason score, serum PSA at diagnosis, age at randomisation, follow-up time, and vital status were extracted from the ERSPC database. Four risk categories at diagnosis were defined: 1, low; 2, intermediate; 3, high; 4, metastatic disease. PSA (≤100 or >100 ng/ml) was used as the indicator of metastasis.
Outcome measurements and statistical analysis
Incidence rate ratios (IRRs) for screening versus control arm by risk category at diagnosis and …
学术搜索中的文章
C Buzzoni, A Auvinen, MJ Roobol, S Carlsson… - European urology, 2015